OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
May 28, 2022
Oral doses of 3 Janus kinase inhibitors show the therapies out-performed placebo in all outcomes measured in patients with moderate-to-severe AD.
May 19, 2022
About half of a cohort of nearly 800 patients said they experience ocular symptoms.
May 12, 2022
Most research into the rare condition is focused on therapies and diagnostics, but investigators say it is important to better understand the disease’s impact on those around the patient.
The new analysis suggests the infections rarely leads to discontinuation in patients with atopic dermatitis.